Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status by Palmqvist, S et al.
Performance of Fully Automated Plasma Assays as Screening
Tests for Alzheimer Disease–Related β-Amyloid Status
Sebastian Palmqvist, MD, PhD; Shorena Janelidze, PhD; Erik Stomrud, MD, PhD; Henrik Zetterberg, MD, PhD;
Johann Karl, PhD; Katharina Zink; Tobias Bittner, PhD; Niklas Mattsson, MD, PhD; Udo Eichenlaub, PhD;
Kaj Blennow, MD, PhD; Oskar Hansson, MD, PhD
IMPORTANCE Accurate blood-based biomarkers for Alzheimer disease (AD) might improve
the diagnostic accuracy in primary care, referrals to memory clinics, and screenings for AD
trials.
OBJECTIVE To examine the accuracy of plasma β-amyloid (Aβ) and taumeasured using fully
automated assays together with other blood-based biomarkers to detect cerebral Aβ.
DESIGN, SETTING, AND PARTICIPANTS Two prospective, cross-sectional, multicenter studies.
Study participants were consecutively enrolled between July 6, 2009, and February 11, 2015
(cohort 1), and between January 29, 2000, and October 11, 2006 (cohort 2). Data were
analyzed in 2018. The first cohort comprised 842 participants (513 cognitively unimpaired
[CU], 265 with mild cognitive impairment [MCI], and 64with AD dementia) from the Swedish
BioFINDER study. The validation cohort comprised 237 participants (34 CU, 109MCI, and 94
AD dementia) from a German biomarker study.
MAIN OUTCOME ANDMEASURES The cerebrospinal fluid (CSF) Aβ42/Aβ40 ratio was used as
the reference standard for brain Aβ status. Plasma Aβ42, Aβ40 and tau weremeasured using
Elecsys immunoassays (Roche Diagnostics) and examined as predictors of Aβ status in logistic
regressionmodels in cohort 1 and replicated in cohort 2. Plasma neurofilament light chain
(NFL) and heavy chain (NFH) and APOE genotype were also examined in cohort 1.
RESULTS Themean (SD) age of the 842 participants in cohort 1 was 72 (5.6) years, with a range
of 59 to 88 years, and 446 (52.5%)were female. For the 237 in cohort 2,mean (SD) agewas 66
(10) years with a range of 23 to 85 years, and 120 (50.6%)were female. In cohort 1, plasma
Aβ42 and Aβ40predicted Aβ statuswith an area under the receiver operating characteristic
curve (AUC) of 0.80 (95%CI, 0.77-0.83).When addingAPOE, the AUC increased significantly
to 0.85 (95%CI, 0.82-0.88). Slight improvementswere seenwhen adding plasma tau (AUC,
0.86; 95%CI, 0.83-0.88) or tau andNFL (AUC, 0.87; 95%CI, 0.84-0.89) to Aβ42, Aβ40 and
APOE. The results were similar in CU and cognitively impaired participants, and in younger and
older participants. Applying the plasma Aβ42 and Aβ40model from cohort 1 in cohort 2
resulted in slightly higher AUC (0.86; 95%CI, 0.81-0.91), but plasma tau did not contribute.
Using plasma Aβ42, Aβ40, andAPOE in an AD trial screening scenario reduced positron
emission tomography costs up to 30% to 50%depending on cutoff.
CONCLUSIONS AND RELEVANCE Plasma Aβ42 and Aβ40measured using Elecsys
immunoassays predict Aβ status in all stages of ADwith similar accuracy in a validation
cohort. Their accuracy can be further increased by analyzing APOE genotype. Potential future
applications of these blood tests include prescreening of Aβ positivity in clinical AD trials to
lower the costs and number of positron emission tomography scans or lumbar punctures.
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A key hallmark of Alzheimer disease (AD) is the gradualaccumulation of β-amyloid (Aβ) in the brain, whichstarts decades before the onset of cognitive symp-
toms. Detection of abnormal Aβ accumulation (Aβ positivity)
may support the clinical diagnosis of AD1,2 and is essential for
includingparticipants inclinicalADtrials targetingAβ.3β-Amy-
loid can be detected in vivo using positron emission tomog-
raphy (PET) with ligands that bind to Aβ fibrils or bymeasur-
ingthe levelsof thepeptideAβ1-42 (Aβ42) incerebrospinal fluid
(CSF).4Alzheimerdisease affects 1 in 10persons aged65years
and older and is expected to affect more than 100 million
people by 2050.5,6 The costs and limited access to PET or CSF
analysis may restrict their use to aminority of cases. There is
thus a great need for readily available methods that can de-
tect brain Aβ, and perhaps the most desirable goal has been
to establish blood-based biomarkers of Aβ. Many candidate
blood biomarkers have failed in replication studies,7,8 but
somewhat promising results have been seen for plasma tau,
neurofilament lightchain (NFL), andcombinationsofAβ42and
Aβ40.9-17 Although there are diagnostic inconsistencies re-
garding the plasma Aβ42/Aβ40 ratio in older studies,18 more
recent studies havedemonstrated that it correlateswith brain
Aβ and can differentiate patients with AD from healthy con-
trolparticipants.12,13Most recently,2 independentgroupsdem-
onstrated improvedaccuracy forplasmaAβ42/Aβ40using im-
munoprecipitation–mass spectrometry assays.19,20 Although
these studies are promising and show the potential of plasma
Aβ as a trueADbiomarker, they are costly andneed extensive
developmentbefore they canbe implemented inprimary care
or in large screenings where cost-effective, fully automated,
high-throughput, and highly reliable analysis methods are
needed.
MeasuringplasmaAβpresents thesamechallengesasmea-
suring CSF Aβ in that several analysis methods exist and uni-
fiedcutoffshavebeendifficult toestablish,evenusingthesame
assay, owing to high variability between laboratories and as-
saybatches.21,22Recently, fullyautomated immunoassayshave
been developed by several different vendors with improved
reliability andprecision forCSFAβand tau species.23-25 For ex-
ample, for the Elecsys immunoassays (Roche Diagnostics), it
has been shown that CSF cutoffs established in oneEuropean
cohort could be applied to another independent cohort in the
United States to determine amyloid PET status with high
accuracy.24
Using these newly developed Elecsys assays for detec-
tion ofAβ42,Aβ40, and tau, our aimswere to examine the ac-
curacy of plasmaAβ42, Aβ40, and tau to estimate Aβ positiv-
ity,whether theaccuracy couldbe improvedbyaddingplasma
neurofilament (light and heavy chain) andAPOE genotype to
the models, and how the Elecsys assays perform in an inde-
pendent validation cohort.
Methods
Participants
Thestudypopulationwas includedfromtheprospectiveSwed-
ishBioFINDERStudy,whichenrolledparticipantsbetweenJuly
6, 2009, to February 11, 2015, from the southern part of
Sweden. Of all 892 participants in BioFINDER’s control, mild
cognitive symptoms,andADcohorts,plasmasampleswerehe-
molyzedornot available in sufficient amount for 50 individu-
als. Thus, 842 participants could be included in the present
study. They were classified as cognitively unimpaired26 (CU;
513 participants, of whom 195 had subjective cognitive
decline)27; mild cognitive impairment28 (MCI; 265 partici-
pants); orADdementia2 (64participants). In subsample analy-
ses, we grouped the population into CU and cognitively im-
paired (MCI + AD), because all participants with AD were Aβ
positive and therefore couldnotbeexamined separatelyusing
Aβ status as outcome. Studydesign and specific inclusion and
exclusion criteria are described elsewhere29 (eMethods in the
Supplement). The studywas approved by theRegional Ethics
Committee in Lund, Sweden, and all participants gave their
written informed consent to participate in the study. For the
independentvalidationcohort, the studywasapprovedby the
ethical committee of the Medizinische Hochschule in Han-
nover and the ethical committee of theUniversity ofUlm, and
all participants gave written informed consent.
Plasma and CSF Procedures
Bloodsampleswerecollectedat the sametimeasCSFsamples,
and the collectionwasperformed in themorningwithpartici-
pants not fasting. Blood sampleswere collected and analyzed
according to a standardized protocol. For each study partici-
pant, blood was collected in 6 EDTA-plasma tubes (Vacu-
tainer K2EDTA tube; BD Diagnostics) and centrifuged (2000
g, 4°C) for 10minutes. After centrifugation, plasma from all 6
tubes was transferred into one 50-mL tube (62.547.254,
Sarstedt), mixed, and 1mLwas aliquoted into polypropylene
tubes (72.694.100; Sarstedt) and stored at –80°Cwithin 30 to
60minutes of collection. All plasma samples went through 1
freeze-thaw cycle before the analysis, when 300 μL was fur-
ther aliquoted into Lobind tubes (72.704.600; Sarstedt). The
current standardized protocol is consistent with recent
findings that blood must be centrifuged within 1 hour and
frozen shortly thereafter; however, up to 3 freeze-thawcycles
and 5 tube transfers donot affect plasmaAβ and tau values.30
Key Points
Question Do plasma levels of β-amyloid 42, β-amyloid 40, and
tau detect cerebral β-amyloid status whenmeasured using fully
automated immunoassays?
Findings In 2 cross-sectional studies, plasma β-amyloid 42 to
β-amyloid 40 ratio, measured using immunoassay, accurately
predicted cerebral β-amyloid status in all stages of Alzheimer
disease in the BioFINDER cohort (n = 842) and in an independent
validation cohort (n = 237). The diagnostic accuracy was further
increased by analyzing APOE genotype.
Meaning Blood-based β-amyloid 42 and β-amyloid 40 ratio
together with APOE genotypemay be used as prescreening tests
in primary care and in clinical Alzheimer disease trials to lower the
costs and number of positron emission tomography scans and
lumbar punctures.
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Lumbar puncture and CSF handling followed a structured
protocol.31 Plasma and CSF Aβ42, Aβ40, total tau (tau), and
phosphorylated tau (P-tau; only in CSF) were analyzed using
the Elecsys immunoassays on a cobas e 601 analyzer (Roche
Diagnostics) at the Clinical Neurochemistry Laboratory, Uni-
versity of Gothenburg, Sweden. Additional assay data (also
including NFL and neurofilament heavy chain [NFH] analy-
ses) can be found in the eMethods and eTables 1 and 2 in the
Supplement.
Reference Standard for Aβ Status
β-Amyloid statuswasdeterminedusing theElecsysCSFAβ42/
Aβ40ratio,which isa ratio thathasbeenvalidatedagainstamy-
loid PET statuswithmore than 90%agreement.32-34 Anunbi-
ased cutoff of less than0.059wasused todefineAβpositivity
based on mixture modeling statistics, which previously has
proved toprovide robust andaccurate thresholds.35,36 Ina sec-
ondary analysis (eFigure 3 and eFigure 4 in the Supplement),
we used the Elecsys CSF P-tau/Aβ42 ratio to define Aβ posi-
tivity, using the predefined cutoff of 0.022 or greater.24
Independent Validation Cohort
All 237 participants of this study were enrolled between
January 29, 2000, and October 11, 2006, at 2 clinical sites in
Germany, Ulm and Hannover, as part of a prospective valida-
tion studyofnewbiomarkers for theearlydiagnosisofAD.The
participants were classified as having CU (n = 34), MCI
(n = 109),37 orADmild dementia38 (Mini-Mental State Exami-
nation score >22; n = 94). Specific inclusion/exclusion crite-
ria and CSF and blood collection procedures30 are described
in the eMethods in the Supplement. The cutoff of CSF Aβ42/
Aβ40 of less than 0.059 established in BioFINDER to define
Aβpositivitywasalsoused in thevalidationcohort after a thor-
ough assessment of the CSF Aβ42/Aβ40 distribution. As in
BioFINDER, the previously published cutoff of CSF P-tau/
Aβ42 0.022 or greater24 was used as a secondary reference
standard for Aβ status also in the validation cohort.
Statistical Analysis
According to previous publications39,40 and present analyses
(eResults in the Supplement), APOE (OMIM:107741) genotype
analyzed frombloodwasgrouped into (A)ε2/ε2orε2/ε3; (B)ε3/
ε3; (C) ε2/ε4 or ε3/ε4; and (D) ε4/ε4. APOE ε3/ε3 was the
reference category in the statistical models. β-Amyloid status
waspredicted in logistic regressionmodels toproduceestimates
of the predictors, probabilities for Aβ positivity, and resulting
areaunderthereceiveroperatingcharacteristiccurve(AUC).The
examinedpredictors inBioFINDERweretheplasmabiomarkers
Aβ42, Aβ40, tau, NFH, and NFL and APOE genotype. The
modelswere built using theAkaike information criterion (AIC)
to evaluate the model fit. A predictor was kept in the model if
AIC improvedsignificantly (adecrease inAICofat least2,noted
as “ΔAIC -2”).41 Differences in AUCs were compared using
DeLong statistics.42 In the replication analysis, the models
(intercepts and estimates) established in BioFINDER were
appliedtothevalidationcohort.Theresultingprobabilities from
the validation cohort were used to calculate the AUCs (only
plasma Aβ42, Aβ40, and tau were available in this cohort).
Additional statistical methods are described in the eMethods
in the Supplement. SPSS version 24 (IBM) andR version 3.4 (R
Foundation for Statistical Computing) were used for the
statistical analyses. Two-sided P < .05 indicated statistical
significance.
Results
Among the 842 study participants in BioFINDER, mean (SD)
agewas 72.0 (5.6) years, and446 (52.5%)were female. Demo-
graphic and clinical data for the study participants in
BioFINDERare shown inTable 1. In the totalBioFINDERpopu-
lation of 842, 368were positive for Aβ (prevalence, 44%); 147
of 513withCU (29%)werepositive; 157of 265 (60%)withMCI;
and, by definition, all 64 (100%) with AD dementia.
Correlations Between Plasma and CSF Biomarkers
In the whole BioFINDER population, there were statistically
significant positive correlations between all plasma and cor-
respondingCSFbiomarkers (eTable 3 in the Supplement). The
correlations were similar within diagnostic subgroups (eFig-
ure 1 and eTable 3 in the Supplement).
Plasma Aβ and tau Levels in Diagnostic Groups
In BioFINDER, plasma levels of Aβ42, Aβ40, and Aβ42/Aβ40
were decreased in Aβ-positive (CSF Aβ42/Aβ40 ≤ 0.059)
comparedwithAβ-negative (CSFAβ42/Aβ40 > 0.059)partici-
pants (Aβ42, P < .001; Aβ40 P = .003, Aβ42/Aβ42, P < .001;
Figure 1A-C). When comparing Aβ groups stratified by diag-
nostic subgroup, plasma levels of Aβ42 were lower in the CU
Aβ-positive, MCI Aβ-positive and AD Aβ-positive dementia
groups compared with the CU Aβ-negative and MCI Aβ-
negative groups (P < .001 for all; Figure 1D). The decrease in
plasmaAβ42wasmorepronounced inADAβ-positivedemen-
tia comparedwithCUAβ-positive andMCIAβpositive groups.
PlasmaAβ40 levelswere lower in the ADAβ-positive demen-
tia group comparedwith all other groups (P < .001 for all), but
there were no differences between CU Aβ-negative, CU Aβ-
positive, and MCI Aβ-positive participants (Figure 1E). The
plasmaAβ42/Aβ40 ratiowas lower in theCUAβ-positive,MCI
Aβ-positive, and ADAβ-positive dementia groups than in the
CU Aβ-negative and MCI Aβ-negative groups with no differ-
ences across the Aβ-positive groups (Figure 1F). The signifi-
cant findingswerevery similarwhenadjusting for age and sex
(data not shown). Comparisons of plasma tau, NFL, and NFH
are shown in eFigure 2 in the Supplement.
Accuracy of Plasma Aβ42 and Aβ40
for Predicting Brain Aβ Positivity
The results from the logistic regressionmodels in BioFINDER
of all tested single and combined biomarkers are shown in
eTables 4, 5, and 6 in the Supplement (includingAUC andAIC
values). The receiver operating characteristic curves andAUCs
of selected biomarkers for predicting Aβ positivity are shown
in Figure 2A and B (sensitivity, specificity, and cutoffs are
shown in Table 2). The plasma Aβ42/Aβ40 ratio predicted Aβ
positivitywith anAUCof0.77 (95%CI, 0.74-0.81) in thewhole
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BioFINDERpopulation.UsingplasmaAβ42andAβ40as sepa-
rate predictors in a logistic regression resulted in a slightly but
significantly betterAUC (0.80; 95%CI, 0.77-0.83;P = .01) and
a better model fit (ΔAIC, –66). We also tested the accuracy of
the biomarkers in different age groups and in those with and
without cognitive impairment (Figure 3; eTable4andeTable6
in the Supplement), with similar results (AUC ±0.02 com-
pared with the total population).
Aβ DetectionWith Additional Predictors
The accuracy of predicting Aβ status was further examined
by adding APOE genotype, and plasma levels of tau, NFL,
and NFH to plasma Aβ42 and Aβ40 in logistic regression
models (Figure 2A-B). When adding plasma tau, AUC
increased nonsignificantly to 0.81 (95% CI, 0.78-0.84) and
further improved the model fit (ΔAIC, –27). However, when
instead adding APOE genotype to plasma Aβ42 and Aβ40,
AUC increased significantly from 0.80 to 0.85 (95% CI, 0.82-
0.88; P < .001; Figure 2A-B; eTable 4 in the Supplement).
Adding plasma tau to plasma Aβ42, Aβ40, and APOE
increased the AUC slightly to 0.86 (95% CI, 0.83-0.88; ΔAIC,
–20). A further slight increase was seen when adding plasma
NFL to plasma Aβ42, Aβ40, tau, and APOE (AUC, 0.87; 95%
CI, 0.84-0.89; ΔAIC –16; Figure 2A-B). The results were simi-
lar in CU and cognitively impaired participants, respectively,
except that plasma tau and NFL were not a significant pre-
dictor in the cognitively impaired group (eTable 4 in the
Supplement). The results were also similar when the CSF
P-tau/Aβ42 ratio was used to define Aβ positivity (eFigure 3
in the Supplement). Plasma NFH did not contribute to Aβ
prediction in addition to plasma Aβ42 and Aβ40 (eTable 5 in
the Supplement).
Independent Validation Cohort
Among the 237 study participants in the independent valida-
tion cohort, mean (SD) age was 66 (10) years with a range of
23 to 85 years, and 120 (50.6%) were female. The demo-
graphiccharacteristicsareshownineTable7 in theSupplement
and the accuracy of the plasma assays in Figure 2C andD. The
AUC for plasma Aβ42 and Aβ40 to predict Aβ positivity was
Table 1. Demographic and Clinical Dataa
Characteristic CU Aβ− (n = 366) CU Aβ+ (n = 147) MCI Aβ− (n = 108) MCI Aβ+ (n = 157) AD Aβ+ (n = 64)
Sex
Male 152 69 76b 79 25
Female 214 78 32 78 39
Age, y 72 (5) 73 (5) 69 (6)b 72 (5) 76 (5)b
APOE genotype, %
1 or 2 ε4 alleles, 19 63b 24 70b 69b
MMSE 28.9 (1.1) 28.6 (1.3) 27.5 (1.8)b 26.7 (1.8)b 21.8 (3.7)b
Delayed recall (ADAS-cog; errors)c 2.2 (1.9) 3.2 (2.3)b 5.7 (2.4)b 7.0 (2.1)b 8.6 (1.6)b
CSF
Aβ42, pg/mL 1665 (596) 819 (303)b 1572 (605) 706 (256)b 671 (315)b
Aβ40, ng/mL 18.2 (5.2) 19.5 (5.9)d 17.3 (5.7) 17.8 (5.0) 17.9 (6.2)
Aβ42/Aβ40 0.091 (0.016) 0.042 (0.009)b 0.090 (0.014) 0.040 (0.098)b 0.037 (0.009)b
T-tau, pg/mL 209 (62) 309 (112)b 209 (76) 341 (136)b 384 (143)b
P-tau, pg/mL 17.5 (5.3) 28.5 (12.0)b 16.9 (6.4) 32.2 (14.5) b 36.3 (16.3)e
NFL, pg/mL 918 (490) 1216 (842)b 1648 (1517)b 1531 (1195)b 2002 (1835)b
NFH, pg/mL 504 (190) 584 (241)b 641 (463)b 637 (303) b 821 (687)b
Plasma
Aβ42, pg/mL 32.8 (4.9) 29.6 (4.3)b 33.1 (5.2) 30.3 (4.5)b 23.3 (8.2)b
Aβ40, pg/mL 482 (63.3) 479 (67.5) 495 (83.2) 492 (75.4) 380 (131.7)e
T-tau, pg/mL 16.6 (4.7) 17.9 (5.4)e 18.7 (6.1)b 19.1 (5.2)b 16.7 (6.0)
Aβ42/Aβ40 0.068 (0.007) 0.062 (0.007)b 0.067 (0.007) 0.062 (0.006)b 0.062 (0.010)b
NFL, pg/mL 21.0 (11.8) 29.1 (59.6)e 28.3 (28.4)b 29.0 (17.9)b 43.8 (28.7)b
NFH, pg/mLf 51.4 (68.2) 53.7 (48.7) 59.7 (55.1) 65.9 (56.6)b 79.8.4 (77.0)b
Abbreviations: Aβ, β-amyloid; Aβ+, Aβ positive; Aβ−, Aβ negative;
CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination;
NHL, neurofilament heavy chain; NFL, neurofilament light chain.
a β-Amyloid status was defined based on a CSF Aβ42/Aβ40 cutoff of0.059.
Data are shown as mean (SD) unless otherwise specified. Demographic
factors, clinical characteristics, and biomarkers levels were compared using χ2
test and 1-way analysis of variance (not adjusted for multiple comparisons).
Neurofilament light chain and NFH values were ln-transformed before the
analysis. In the receiver operating characteristic subanalyses, the mild
cognitive impairment and Alzheimer disease cohorts are combined as
cognitively impaired (Figure 3A and B; eFigure 3C and D; eTable 4 in the
Supplement). When calculating the Aβ42/Aβ40 ratio, picomolar per milliliter
was used for both peptides.
bP < .001 compared with CU Aβ−.
c Data were missing for 1 CU Aβ−, 1 MCI Aβ−, 8MCI Aβ+ and 5 AD Aβ+
individuals.
dP < .05.
e P < .01.
f Data were missing for 6 CU Aβ−, 3 CU Aβ+, 2 MCI Aβ−, 5 MCI Aβ+ and 5 AD
Aβ+ individuals.
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Figure 1. Levels of Plasma β-Amyloid (Aβ) Biomarkers
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Plasma Aβ42 (A), Aβ40 (C), and the plasma Aβ42/Aβ40 ratio (E) in the Aβ-positive (Aβ+) (CSF Aβ42/Aβ40  0.059) and Aβ-negative (Aβ−)
(CSF Aβ42/Aβ40 > 0.059) groups. Plasma Aβ42 (B), Aβ40 (D), and the plasma Aβ42/Aβ40 ratio (F) in the CU, MCI, and AD participant groups stratified by Aβ
status. The dotted lines indicate median levels in the CU Aβ-negative group. P values are calculated from t test (A, C, E) or 1-way analysis of variance and post hoc
tests with the statistical significance set to P < .005 (.05/10.00) to account for the Bonferroni correction (B, D, F). The significant findings were similar when
adjusting for age and sex (data not shown). Group comparisons of plasma tau, NFH, and NFL are shown in eFigure 2 in the Supplement. AD, Alzheimer disease;
CSF, cerebrospinal fluid; CU, cognitively unimpaired; MCI, mild cognitive impairment; NFH, neurofilament heavy chain; and NFL, neurofilament light chain.
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0.86 (95%CI,0.81-0.91)whenapplying theestimates fromthe
model established in BioFINDER (compared with an AUC of
0.80, 95% CI 0.77-0.83 in BioFINDER). When applying the
BioFINDERmodel that included plasmaAβ42, Aβ40, and tau
in thevalidation cohort, theAUCwas slightly lower thanwhen
using only plasma Aβ42 and Aβ40 (AUC, 0.84; 95% CI, 79-
89).With the alternative reference standard forAβ status (CSF
P-tau/Aβ42 ≥ 0.022; eFigure 4 in the Supplement), the accu-
racywas slightly lower for plasmaAβ42 andAβ40 (AUC,0.83;
95% CI, 0.78-0.89) but still better than the corresponding re-
sults in the BioFINDER cohort (AUC, 0.79; 95%CI, 0.76-0.82;
eFigure 3 in the Supplement). Sensitivities and specificities
Figure 2. Receiver Operating Characteristic (ROC) Analysis of Plasma Biomarkers
in the BioFINDER and Validation Cohorts
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Optimized ROC curves and
corresponding areas under the curve
(AUCs) for plasma Aβ together with
the additional predictors, APOE,
plasma tau, and neurofilament light
chain (NFL) to assess accuracy when
predicting Aβ positivity (crebrospinal
fluid Aβ42/Aβ40  0.059) in the
BioFINDER (A and B, n = 842); and
the replication of thesemodels
(C and D, n = 237) in the validation
cohort using the estimates and
intercepts established in BioFINDER.
APOE genotype and NFL were not
available in the validation cohort.
Error bars indicate 95% CIs.
ROC analyses in subpopulations can
be found in Figure 3 and eTable 4 and
6 in the Supplement. Sensitivities and
specificities are shown in Table 2.
ROC analyses using the alternative
reference standard for Aβ positivity
(CSF P-tau/Aβ42  0.022) are shown
in eFigures 3 and 4 in the
Supplement.
Table 2. Sensitivity and Specificity for Aβ Status in the BioFINDER Cohort and the Validation Cohort
Plasma Biomarkers Cutoffa
% (95% CI)
Sensitivity Specificity
BioFINDER cohort
Aβ42/Aβ40 ratio 0.065 75 (68-80) 72 (65-77)
Aβ42, Aβ40 0.45 73 (65-78) 76 (68-80)
Aβ42, Aβ40, tau 0.36 86 (78-90) 68 (61-72)
Aβ42, Aβ40, NFL 0.38 84 (76-88) 70 (62-74)
Aβ42, Aβ40, APOE 0.29 88 (82-92) 68 (58-72)
Aβ42, Aβ40, tau, NFL, APOE 0.52 73 (64-78) 86 (77-89)
Validation cohort
Aβ42/Aβ40 ratio 0.065 70 (61-80) 73 (61-81)
Aβ42, Aβ40 0.45 89 (80-95) 69 (54-81)
Aβ42, Aβ40, tau 0.36 89 (74-94) 64 (49-74)
Abbreviations: Aβ, β-amyloid; NFL, neurofilament light chain.
a Cutoffs were determined based on the highest Youden index
(sensitivity + specificity – 1) for Aβ positivity in the BioFINDER cohort. The
cutoffs were then replicated in the validation cohort. Cutoffs are from the
probabilities from the corresponding logistic regressionmodels, except for
Aβ42/Aβ40where the actual ratio of the biomarker levels constitute the
cutoff. Aβ status (reference standard) was determined using the cerebrospinal
fluid Aβ42/40 ratio (<0.059). The 95% CIs were computed using 2000
stratified bootstrap replicates. Neurofilament light chain and APOE genotype
were not available in the validation cohort.
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Figure 3. Receiver Operating Characteristic (ROC) Analysis of Plasma Biomarkers
in Subpopulations in BioFINDER
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ROC curves and corresponding areas
under the curve (AUCs) from logistic
regressionmodels for plasma Aβ
together with the additional
predictors APOE, plasma tau, and
neurofilament light chain (NFL), to
assess accuracy when detecting Aβ
positivity (cerebrospinal fluid
Aβ42/Aβ40  0.059) in cognitively
unimpaired participants (A and B,
n = 513), cognitively impaired
participants (C and D, n = 329), the
younger half of the cohort (E and F,
n = 428; 60-72 y), and the older half
of the cohort (G and H, n = 414;
73-88 y). Cognitively unimpaired
comprised of cognitively healthy
controls and participants with
subjective cognitive decline.
Cognitively impaired comprised of
participants with mild cognitive
impairment and Alzheimer disease
dementia. AUC indicates area under
the curve; and NFL, neurofilament
light chain.
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using the cutoffs established in BioFINDER are shown in
Table2. PlasmaNFH,NFL, andAPOEgenotypewerenot avail-
able in the validation cohort.
Cost-Benefit Analysis
Finally, we performed a cost benefit analysis (eFigure 5 in the
Supplement) where we show a scenario in which 1000
Aβ-positive participants are included in a trial where the
screening cost for Aβ PET is $4000 per participant.43 For
example, using the highest Youden index cutoff (Table 2) for
plasma Aβ42, Aβ40, and APOE reduces the number of PET
scans by approximately 800 and lowers the PET costs by
approximately $3.2 million (from a total cost of approxi-
mately $9.2 million).
Discussion
In this study of 842 participants, we found that plasma Aβ42
and Aβ40 using the fully automated Elecsys platform
detected abnormal levels of Aβ in the brain with an AUC of
0.80 (Figure 2A and B). The addition of APOE genotype
increased the AUC significantly to 0.85 (Figure 2A and B).
Plasma tau and NFL had a slight effect on the accuracy (AUC,
+0.01 to 0.02; Figure 2A and B). The results were similar in
cognitively impaired and unimpaired and older and younger
participants (Figure 3), with the exception that plasma tau
and NFL generally did not improve accuracy in addition to
plasma Aβ and APOE genotype in cognitively impaired par-
ticipants (eTable 4 in the Supplement). When applying the
plasma Aβ42 and Aβ40 model from BioFINDER to the inde-
pendent validation cohort (n = 237), the AUC was greater
compared with BioFINDER (AUC, 0.86; 95% CI, 0.81-0.91),
but no improvement was seen when adding plasma tau
(Figure 2C and D).
Although previous studies have found associations
between CSF and PET Aβ and plasma Aβ using different
immunoassays,7,12-14,44,45 the present Elecsys assays pro-
duced among the best accuracies and they are the first fully
automated assays to have these greater accuracies. In
mass spectrometry–based techniques, 2 recent studies have
provided overall better accuracies for plasma Aβ42/Aβ40
(AUC, 0.84-0.97 depending on population and reference
standard).19,20 However, these are labor-intensive, time-
consuming, low-throughput methods that currently are
not feasible to implement in clinical practice on a large
scale. Fully automated Elecsys assays, on the other hand,
are already implemented in many clinical chemistry labora-
tories worldwide that provide analyses (eg, for primary
care).
Historically, the ratio of plasma Aβ42 to Aβ40 has been
used to optimize the concordance with CSF or PET Aβ. Here,
Aβ40 acts as a reference peptide that accounts for interindi-
vidual variability in the overall Aβ production and CSF turn-
over. We found that instead of using the fixed ratio of Aβ42/
Aβ40, both the model fit (AIC) and accuracy (AUC) were
slightly but significantly improved when the model was
adjusted for Aβ40 concentrations independent of Aβ42 (ie,
used as a separate predictor in the logistic regression models)
(AUC 0.77 vs 0.80; P = .01; ΔAIC –66; eTable 4 in the Supple-
ment). As a single additional biomarker to Aβ42 and Aβ40,
APOE genotype increased the accuracy most markedly, from
AUC 0.80 to 0.85 (P < .001) (Figure 2A and B; eTable 4 in the
Supplement). Plasma tau increased the AUC slightly, and pro-
vided a better model fit (ΔAIC –27), but clinically this is not
comparable with the contribution CSF tau has combinedwith
CSF Aβ42,24 and improved plasma tau assays are probably
needed in the future, such as measurement of specifically
phosphorylated tau,46 to increase the added value of plasma
tau to plasma Aβ42 and Aβ40.
Despite the present and previous results showing rela-
tivelyhighcorrelationsbetweenplasmaandCSFNFL (eTable3
in the Supplement and the study by Hansson et al47), we saw
amodest increase in accuracy in addition to plasmaAβ42 and
Aβ40(Figure2;eTable4 in theSupplement).BecauseNFLgen-
erally is late biomarker in the disease process and a non–AD
specific biomarker for axonal degeneration,15 the poor result
couldbebecausemostof theparticipants (513of842)werecog-
nitively unimpaired and only 64 had AD dementia. Com-
paredwithplasma tauandNFL,plasmaNFHhadapoorerper-
formance and did not improve accuracy (eTable 5 in the
Supplement). However, 101 plasmaNFHmeasurementswere
below the detection limit of the assays, and development of
more sensitive plasmaNFHassays is thuswarranted to estab-
lish whether this biomarker could further improve the diag-
nostic performance of plasma Aβ.
Overall, the accuracies of the Aβ42 and Aβ40 assays are
not sufficient to be used on their own as a clinical test of Aβ
positivity; additional assay development is needed before
this can be recommended, possibly together with other
blood biomarkers and screening tools in diagnostic algo-
rithms. In the present study, we showed that the Aβ assays
perform similarly in CU populations with lower prevalence of
Aβ positivity (Figure 3A and B; Aβ-positive prevalence, 29%).
Nonetheless, further studies would be valuable in popula-
tions with lower prevalence of Aβ positivity, such as primary
care settings, as well as more heterogeneous dementia
cohorts with different neurodegenerative disorders. To some
extent, the generalizability of the BioFINDER results has
already been shown in the present study where the plasma
Aβ42 and Aβ40 model established in BioFINDER could be
applied in the independent validation cohort with better
accuracy (AUC, 0.86 vs 0.80; Figure 2). This robust result is
similar to what has been shown when using the Elecsys
assays for CSF to establish a cutoff in one cohort and replicat-
ing it in a second cohort.24
Limitations
Limitations of the present validation analysis include the
lack of APOE data, the lack of improvement when replicat-
ing the model that included plasma tau, and the smaller
population size, resulting in a lack of analyses in subpopula-
tions. The latter was, however, tested in BioFINDER and the
accuracies were similar in different subsamples including
CU (Figure 3A and B) and younger participants (Figure 3E
and F) where Aβ positivity might be more difficult to iden-
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tify using alternative methods such as cognitive testing and
age stratification.40
Conclusions
From a practical perspective, we believe that themost advan-
tageous future use of optimized bloodAβ assays is as a screen-
ing tool for identifyingsubjects at ahigher riskofbeingAβposi-
tive. They could, for example, be applied as an initial test
togetherwithothernoninvasive,cost-efficient tools thataid the
decisionaboutwhomageneralpractitionershouldrefer for fur-
ther investigationatmemoryclinicswhereCSForPETandmore
extensive clinical assessment could be used to support the AD
diagnosis. Another useful setting for the blood biomarkers are
clinicalADtrials enrollingAβ-positiveparticipants,where they
can be used for prescreening to minimize the number of un-
necessary (Aβ-negative) lumbar punctures and Aβ PET scans,
aswell as lowering the costs for the examinations up to 30% to
50%depending on the cutoff (eFigure 5 in the Supplement).48
Although further validation studies areneeded, this illustrates
thepotentialusefulnessbloodassaysmighthave,especiallycon-
sidering the ongoing great need to recruit large cohorts for AD
drug trials in preclinical and prodromal stages.
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